Form HLTH5385 Pharmacare Special Authority Request - Natalizumab (Tysabri) for Multiple Sclerosis - British Columbia, Canada

Form HLTH5385 Pharmacare Special Authority Request - Natalizumab (Tysabri) for Multiple Sclerosis - British Columbia, Canada is used to request special authorization for the medication Natalizumab (Tysabri) for the treatment of Multiple Sclerosis in British Columbia, Canada.

The Form HLTH5385 Pharmacare Special Authority Request for Natalizumab (Tysabri) for Multiple Sclerosis in British Columbia, Canada is typically filed by the patient or their healthcare provider.

Form HLTH5385 Pharmacare Special Authority Request - Natalizumab (Tysabri) for Multiple Sclerosis - British Columbia, Canada - Frequently Asked Questions (FAQ)

Q: What is the purpose of Form HLTH5385?
A: Form HLTH5385 is used to request special authority for the medication Natalizumab (Tysabri) for Multiple Sclerosis in British Columbia, Canada.

Q: What is Natalizumab (Tysabri)?
A: Natalizumab (Tysabri) is a medication used to treat Multiple Sclerosis.

Q: Who can use Natalizumab (Tysabri)?
A: Natalizumab (Tysabri) is used by patients with Multiple Sclerosis who meet specific criteria.

Q: What is special authority?
A: Special authority is a process that allows patients to access specific medications that are not typically covered under regular drug benefit programs.

Q: What are the requirements for special authority for Natalizumab (Tysabri)?
A: The requirements for special authority for Natalizumab (Tysabri) may include specific clinical criteria and documentation from the prescribing physician.